Showing 1 - 3 results of 3 for search 'Kathryn Mngadi', query time: 0.03s Refine Results
  1. 1
    Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials

    Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials by Yunda Huang, Logashvari Naidoo, Lily Zhang, Lindsay N. Carpp, Erika Rudnicki, April Randhawa, Pedro Gonzales, Adrian McDermott, Julie Ledgerwood, Margarita M.Gomez Lorenzo, David Burns, Allan DeCamp, Michal Juraska, John Mascola, Srilatha Edupuganti, Nyaradzo Mgodi, Myron Cohen, Lawrence Corey, Philip Andrew, Shelly Karuna, Peter B. Gilbert, Kathryn Mngadi, Erica Lazarus

    Published 2021-02-01
    Get full text
    Article
  2. 2
    Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.

    Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (... by Fatima Laher, Zoe Moodie, Kristen W Cohen, Nicole Grunenberg, Linda-Gail Bekker, Mary Allen, Nicole Frahm, Nicole L Yates, Lynn Morris, Mookho Malahleha, Kathryn Mngadi, Brodie Daniels, Craig Innes, Kevin Saunders, Shannon Grant, Chenchen Yu, Peter B Gilbert, Sanjay Phogat, Carlos A DiazGranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Carter Bentley, Nonhlanhla N Mkhize, Michael N Pensiero, Vijay L Mehra, James G Kublin, Lawrence Corey, David C Montefiori, Glenda E Gray, M Juliana McElrath, Georgia D Tomaras

    Published 2020-02-01
    Get full text
    Article
  3. 3
    Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.

    Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (H... by Zoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg, One B Dintwe, Faatima Laher Omar, Jia J Kee, Linda-Gail Bekker, Fatima Laher, Nivashnee Naicker, Ilesh Jani, Nyaradzo M Mgodi, Portia Hunidzarira, Modulakgota Sebe, Maurine D Miner, Laura Polakowski, Shelly Ramirez, Michelle Nebergall, Simbarashe Takuva, Lerato Sikhosana, Jack Heptinstall, Kelly E Seaton, Stephen De Rosa, Carlos A Diazgranados, Marguerite Koutsoukos, Olivier Van Der Meeren, Susan W Barnett, Niranjan Kanesa-Thasan, James G Kublin, Georgia D Tomaras, M Juliana McElrath, Lawrence Corey, Kathryn Mngadi, Paul Goepfert, HVTN 107 Protocol Team

    Published 2024-03-01
    Get full text
    Article

Search Tools: